Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00422812 · ClinicalTrials.gov registry record · Phase 2
Staccato Prochlorperazine in Migraine (Out Patient)
A Phase 2 study, sponsored by Alexza Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 400
- Enrollment target
NCT00422812 is a Phase 2 study that has completed, run by Alexza Pharmaceuticals. The registered enrollment target is 400 participants.
The verdict
NCT00422812, a Phase 2 study, has completed, sponsored by Alexza Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 400 participants
- Enrollment target
Study Summary
Staccato Prochlorperazine is being developed to treat patients suffering from acute migraine headaches. In October 2005, we completed a 75 patient, multi-center, double-blind placebo-controlled Phase 2A clinical trial in patients suffering from moderate to severe acute migraine headaches. This Phase 2B clinical trial of Staccato Prochlorperazine has been initiated to assess the efficacy and safety in outpatients with migraine headache with or without aura.
Interventions
- DRUG Inhaled Placebo
- DRUG Inhaled PCZ 5 mg
- DRUG Inhaled PCZ 7.5 mg
- DRUG Inhaled PCZ 10 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2006-04 |
| Est. Completion | 2007-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00422812
The ClinicalTrials.gov registry entry for NCT00422812 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexza Pharmaceuticals, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Inhaled Placebo is the first listed.
NCT00422812 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00422812 about?
NCT00422812 is a clinical study titled "Staccato Prochlorperazine in Migraine (Out Patient)". Staccato Prochlorperazine is being developed to treat patients suffering from acute migraine headaches. In October 2005, we completed a 75 patient, multi-center, double-blind placebo-controlled Phase 2A clinical trial in patients suffering from moderate to severe acute migraine headaches. This Phase...
What is the current status of trial NCT00422812?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 400 participants. The study started on 2006-04. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00422812?
The interventions under investigation include: Inhaled Placebo (DRUG), Inhaled PCZ 5 mg (DRUG), Inhaled PCZ 7.5 mg (DRUG), Inhaled PCZ 10 mg (DRUG).
Who is sponsoring clinical trial NCT00422812?
This trial is sponsored by Alexza Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.